Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Impact Of Dietary Vitamin K On The Pharmacological Activity Of FXa Inhibitor, Rivaroxaban, In Man

Farhad Kamali, Salah Abohelaika, Tina T. Biss, Judith Coulson, Hilary Wynne, Paul Murphy

Blood (2013) 122 (21): 4808.

https://doi.org/10.1182/blood.V122.21.4808.4808

Published: 2013

Journal Articles

Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates

Daneyal Syed, Debra Hoppensteadt, Ph.D., Daniel Kahn, Job Harenberg, Prof.,, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 4810.

https://doi.org/10.1182/blood.V122.21.4810.4810

Published: 2013

Journal Articles

Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 Groups of Elderly Healthy Subjects

Michel Meyer Samama, Satoshi Kunitada, A. Oursin, Francois Depasse, Nazneen Haque

Blood (2008) 112 (11): 3026.

https://doi.org/10.1182/blood.V112.11.3026.3026

Published: 2008

Journal Articles

Differential Effects of TAK-442, a Factor Xa Inhibitor, and Ximelagatran, a Thrombin Inhibitor, on Bleeding: Possible Role of Differences in Effects on Factor V-Mediated Feedback on Blood Coagulation Cascade

Noriko Konishi, Katsuhiko Hiroe, Yasuhiro Imaeda, Takuya Fujimoto, Keiji Kubo, PhD, Masaki Kawamura, DVM, PhD

Blood (2008) 112 (11): 5460.

https://doi.org/10.1182/blood.V112.11.5460.5460

Published: 2008

Journal Articles

Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.

Minori Saitoh, PhD, Seiji Kaku, Ph.D, Toshiyuki Funatsu, Ph.D, Hiroyuki Koshio, Ph.D, Tsukasa Ishihara, Ph.D, Fukushi Hirayama, Ph.D, Tomihisa Kawasaki, D.V.M., Ph.D, Masao Sasamata, Ph.D

Blood (2007) 110 (11): 3155.

https://doi.org/10.1182/blood.V110.11.3155.3155

Published: 2007

Journal Articles

Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Alejandro Lazo-Langner, MD, Marc A. Rodger, MD, MSc, Philip S. Wells, MD, MSc

Blood (2005) 106 (11): 913.

https://doi.org/10.1182/blood.V106.11.913.913

Published: 2005

Journal Articles

Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.

Scott Kaatz, DO, FACP, Harvey D. White, Michael Gruber, Gregory W. Albers

Blood (2005) 106 (11): 902.

https://doi.org/10.1182/blood.V106.11.902.902

Published: 2005

Journal Articles

Efficacy of the Direct Thrombin Inhibitor Ximelagatran in Maintaining Small-Diameter Vascular Graft Patency.

Steven P. Schmidt, PhD, Michelle Evancho-Chapman, BS, Amy Deeken, MD, Hans Van Giezen, PhD, Stefan C. Carlsson, MD/PhD

Blood (2005) 106 (11): 1871.

https://doi.org/10.1182/blood.V106.11.1871.1871

Published: 2005

Journal Articles

New anticoagulants

Jack Hirsh, Martin O'Donnell, Jeffrey I. Weitz

Blood (2005) 105 (2): 453–463.

https://doi.org/10.1182/blood-2003-12-4195

Published: 2005

Journal Articles

Risk Factors for Bleeding in Patients with Nonvalvular Atrial Fibrillation Who Are Receiving Anticoagulant Therapy with Ximelagatran or Warfarin: Findings from the SPORTIF III and V Trials.

James D. Douketis, MD, FRCP (C), Karin Arneklev, MSc, Samuel Goldhaber, MD, John Spandorfer, MD, Frank Halperin, MD, Jay Horrow, MD, MS, FAHA

Blood (2004) 104 (11): 528.

https://doi.org/10.1182/blood.V104.11.528.528

Published: 2004

Journal Articles

Ximelagatran Versus Warfarin: A Comparison of Bleeding Outcomes in Patients with Nonvalvular Atrial Fibrillation.

James D. Douketis, MD, FRCP(C), Karin Arneklev, MSc, Samuel Goldhaber, MD, John Spandorfer, MD, Frank Halperin, MD, Jay Horrow, MD, MS, FAHA

Blood (2004) 104 (11): 1765.

https://doi.org/10.1182/blood.V104.11.1765.1765

Published: 2004

Journal Articles

Thrombin Activatable Fibrinolytic Inhibitor Modulation in Heparin Supplemented Plasma: Clinical Considerations.

Michelle Florian-Kujawski, B.S., Debra Hoppensteadt, Ph.D., Marianne Wilmer, Ph.D., Jawed Fareed, Ph.D.

Blood (2004) 104 (11): 3998.

https://doi.org/10.1182/blood.V104.11.3998.3998

Published: 2004

Journal Articles

Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.

Scott D. Berkowitz, MD, Charles W. Francis, MD, Jennifer McElhattan, MS, Clifford W. Colwell, Jr., MD

Blood (2004) 104 (11): 1771.

https://doi.org/10.1182/blood.V104.11.1771.1771

Published: 2004

Journal Articles

Comparison of the Anticoagulant Effect of Melagatran and Lmwh in an Acquired Antithrombin Deficiency in Children with All Treated with L-Asparaginase.

Lesley G. Mitchell, MSc, Stefan Kuhle, MD, Patrica Vegh, Alice Lau, BSc

Blood (2004) 104 (11): 1860.

https://doi.org/10.1182/blood.V104.11.1860.1860

Published: 2004

Journal Articles

Efficacy wnd Bleeding with Ximelagatran and Warfarin after TKR: Pooled Subgroup Analysis of 3 Phase III Trials.

Scott D. Berkowitz, MD, Jennifer McElhattan, MS, Charles W. Francis, MD, Clifford W. Colwell, Jr., MD

Blood (2004) 104 (11): 1777.

https://doi.org/10.1182/blood.V104.11.1777.1777

Published: 2004

NARROW

The Impact Of Dietary Vitamin K On The Pharmacological Activity Of FXa Inhibitor, Rivaroxaban, In Man

Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates

Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 Groups of Elderly Healthy Subjects

Differential Effects of TAK-442, a Factor Xa Inhibitor, and Ximelagatran, a Thrombin Inhibitor, on Bleeding: Possible Role of Differences in Effects on Factor V-Mediated Feedback on Blood Coagulation Cascade

Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.

Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.

Efficacy of the Direct Thrombin Inhibitor Ximelagatran in Maintaining Small-Diameter Vascular Graft Patency.

New anticoagulants

Risk Factors for Bleeding in Patients with Nonvalvular Atrial Fibrillation Who Are Receiving Anticoagulant Therapy with Ximelagatran or Warfarin: Findings from the SPORTIF III and V Trials.

Ximelagatran Versus Warfarin: A Comparison of Bleeding Outcomes in Patients with Nonvalvular Atrial Fibrillation.

Thrombin Activatable Fibrinolytic Inhibitor Modulation in Heparin Supplemented Plasma: Clinical Considerations.

Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.

Comparison of the Anticoagulant Effect of Melagatran and Lmwh in an Acquired Antithrombin Deficiency in Children with All Treated with L-Asparaginase.

Efficacy wnd Bleeding with Ximelagatran and Warfarin after TKR: Pooled Subgroup Analysis of 3 Phase III Trials.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only